[1]CurrentPatentAssignee:BLUEPRINTMEDICINESCORP-US2015/119405,2015,A1
[1]CurrentPatentAssignee:BLUEPRINTMEDICINESCORP-US2015/119405,2015,A1Locationinpatent:Paragraph0178;0183;0184
[1]CurrentPatentAssignee:BLUEPRINTMEDICINESCORP-US2015/119405,2015,A1
[1]CurrentPatentAssignee:BLUEPRINTMEDICINESCORP-US2015/119405,2015,A1
[1]CurrentPatentAssignee:BLUEPRINTMEDICINESCORP-US2015/119405,2015,A1
Title: Dogan-Topal B, et al. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:116-123.
Title: Richard Kim, et al. First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation. EJC. December 2016, Volume 69, Supplement 1, Page S41.